By Maggie Fick and Michael Erman SAN FRANCISCO, Jan 26 (Reuters) - Artificial intelligence has yet to deliver on the most ...

For more than 60 years, this blank slate approach has been the Food and Drug Administration’s gold standard — and for good ...

In A Nutshell Personalized AI “health agents,” virtual drug trials, and automated compliance tools could quietly speed up ...

Corvus Pharmaceuticals, Inc. jumps 165% on Phase 1 soquelitinib atopic dermatitis data; learn key efficacy, funding, and ...

Dyne Therapeutics leverages its FORCE platform to target genetically driven muscle diseases. Read why I am bullish about DYN ...

As drug candidates discovered via AI move into later-stage clinical trials, the technology seems to be doing as promised: ...

There are many ways doctors can get involved in research, from assisting with small projects to becoming a clinical academic. Elisabeth Mahase asks the experts where doctors should start “Start by ...

“We’re at a transformative moment in the biomedical sciences,” says James Lu, an AI scientist at the Agency for Science, Technology and Research Bioinformatics Institute (A*STAR BII) in Singapore.

Pharmaceutical Executive: What trends did you see at this year's JP Morgan Healthcare Conference? Clay Siegall: I’ve been ...

AI prioritizes clinical trials by identifying unmet medical needs, optimizing resource allocation, and focusing on conditions ...

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...